Bristol/Imclone Review Erbitux Pricing For Chronic Care Patients
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol-Myers Squibb and Imclone are considering reducing the price of the oncologic Erbitux (cetuximab) for chronic care patients
You may also be interested in...
Avastin, Erbitux Prices Invite Price Controls, Former NCI Deputy Says In Editorial
The prices set by Genentech and Bristol-Myers Squibb for their recently launched colorectal cancer therapies are an invitation to impose price controls, former Memorial-Sloan Kettering Cancer Center Physician-in-Chief Robert Wittes, MD, wrote in an editorial published by the Washington Post June 15
Barr’s Expanded Thalidomide ANDA Could Increase Likelihood Of A Marketed Generic
Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.
User Fee Deal For Ad Review Funds Stems From PhRMA DTC Principles
A draft agreement between industry and FDA that would assess user fees for "advisory review" of broadcast direct-to-consumer ads prior to initial public dissemination had its genesis in the Pharmaceutical Research & Manufacturers of America's DTC guiding principles